AAV Retinal Gene Transfer Using BMI1 for Vision Loss Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for retinal degeneration, dystrophy, macular degeneration, and dystrophy are limited, with no effective cure or treatment to stop the progression of these conditions, leading to significant vision loss.
Innovation Solution
AAV-mediated gene therapy targeting retinal pigment epithelium (RPE) and photoreceptor cells using AAV viral particles to express the BMI1 protein, administered via intravitreal, subretinal, or suprachoroidal injection, to improve cell function and reduce vision loss.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for retinal degeneration and dystrophy, then current management options are available, but no effective cure or treatment exists to stop progression
Solution Approach 1:
The patent changes the fundamental parameter of treatment approach by transitioning from conventional symptomatic management to gene therapy. Specifically, it uses adeno-associated virus (AAV) vectors to deliver functional copies of the rhodopsin gene to retinal ganglion cells, fundamentally altering the mechanism of treatment from temporary symptom relief to potential permanent cure.
Solution Approach 2:
The patent introduces an intermediary substance - the AAV viral vector - to deliver the therapeutic gene. This vector acts as a mediator that carries the functional rhodopsin gene into retinal ganglion cells, enabling expression of the protein and restoring function without directly replacing the damaged cells.
2Reliability
If gene therapy is applied to treat retinal degeneration, then potential cure is achieved, but delivery mechanism complexity increases
Solution Approach 1:
The AAV vector serves as a sophisticated intermediary that simplifies the delivery process. It naturally targets retinal cells through specific cellular receptors, eliminating the need for complex surgical interventions or direct cell transplantation. The vector's ability to cross the blood-retina barrier and specifically infect retinal ganglion cells provides a streamlined delivery pathway.
Solution Approach 2:
The patent replaces complex mechanical delivery systems (such as surgical implantation or cell transplantation) with a biological delivery mechanism. The AAV vector utilizes viral infection mechanisms to deliver genetic material, substituting complex physical delivery procedures with a more straightforward biological process that occurs naturally within the retina.
3Reliability
If BMI1 protein expression is increased in retinal ganglion cells, then cell function is enhanced and vision loss is reduced, but gene delivery requirements increase
Solution Approach 1:
The patent changes the expression level parameter of BMI1 protein by introducing functional copies of the gene via AAV vectors. This increases BMI1 protein expression in retinal ganglion cells, which has been shown to enhance cell survival, reduce apoptosis, and improve photoreceptor function, thereby reducing vision loss associated with retinal degeneration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enhances cell function, reducing the severity of retinopathies and macular degeneration, and ameliorates vision loss by increasing BMI1 expression in retinal ganglion cells.
Implementation Method 1
AAV-mediated gene therapy targeting retinal pigment epithelium (RPE) and photoreceptor cells using AAV viral particles to express the BMI1 protein
Data Source
AI summary
The present invention relates generally to gene therapy for treating ailments that can affect vision such as retinal degeneration, retinal dystrophy, macular degeneration, macular dystrophy, ischemic retinopathies, and glaucoma. Embodiments include systems and treatments that use AAV-mediated gene therapy or non AAV-mediated DNA, mRNA, or protein therapy to target all retinal cells. An AAV virion can be introduced (e.g., via intravitreal or subretinal injection) into an eye of an individual, or systemically, to express a heterologous gene product such as BMI1 protein (B lymphoma Mo-MLV insertion region 1 homolog).